Related Experiment Video

Updated: Dec 11, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K

MALAT1 overexpression attenuates AS by inhibiting ox-LDL-stimulated dendritic cell maturation via miR-155-5p/NFIA

Li Chen1, Liqun Hu1, Xiang Zhu1

  • 1Department of Gerontology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; Anhui Provincial Hospital, Anhui Medical University , Hefei Anhui, 230001, P.R.China.

Cell Cycle (Georgetown, Tex.)
|August 26, 2020
PubMed

Insights

This study reveals MALAT1 inhibits oxidized LDL-induced dendritic cell maturation in atherosclerosis. Overexpressing MALAT1 reduces atherosclerotic plaque by regulating the miR-155-5p/NFIA axis, offering a potential treatment strategy for atherosclerosis.

Area of Science:

  • Molecular Biology
  • Immunology
  • Cardiovascular Research

Background:

  • Atherosclerosis (AS) involves dendritic cells (DCs) maturation.
  • The role of MALAT1 in AS-related DC maturation requires clarification.

Purpose of the Study:

  • To investigate the function of MALAT1 in oxidized low-density lipoprotein (ox-LDL)-induced DC maturation in AS.
  • To elucidate the regulatory mechanism of MALAT1 in AS.

Main Methods:

  • Immature DCs (iDCs) from healthy volunteers or ApoE-/- mice were treated with ox-LDL.
  • MALAT1, NFIA, and miR-155-5p levels were analyzed.
  • DC maturation markers (CD83, CD86, IL-12, IL-6) were assessed.
  • In vivo studies in AS mice were conducted.

Main Results:

  • Ox-LDL promoted DC maturation markers and upregulated miR-155-5p while downregulating MALAT1 and NFIA.
  • MALAT1 overexpression suppressed ox-LDL-induced DC maturation.
  • MALAT1 acts as a competing endogenous RNA for miR-155-5p, targeting NFIA.
  • MALAT1 overexpression reduced atherosclerotic plaque area in AS mice.

Conclusions:

  • MALAT1 overexpression attenuates AS by inhibiting ox-LDL-stimulated DC maturation via the miR-155-5p/NFIA axis.
  • The MALAT1/miR-155-5p/NFIA axis presents a potential therapeutic target for AS treatment.
Keywords:
MALAT1/miR-155-5p/NFIAOx-LDLatherosclerosiscompeting endogenous RNAdendritic cells

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.3K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.4K

Related Concept Videos

Inflammation01:38

Inflammation

Overview
60.7K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
568
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
232
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
250